Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatmentAmplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. To view media story please click here. Posted on June 28th, 2021 . Updated on September 16th, 2021 by Amplia Therapeutics